Update on Merkel cell carcinoma
|
|
- Gwen Hicks
- 5 years ago
- Views:
Transcription
1 Merkel cell carcinoma: Diagnosis, staging, sentinel lymph node biopsy and prognostic markers Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology The University of Texas MD Anderson Cancer Center Executive Officer Translational Research Program The Alliance for Clinical Trials Merkel cell carcinoma Described 5 cases of trabecular carcinoma of the skin Tumors consisted of irregular, angular, anastomosing trabeculae infiltrating among dermal collagen as cords Cells with oval, vesicular nuclei and indiscernible cytoplasm Update on Merkel cell carcinoma Merkel cell carcinoma Diagnosis and molecular pathogenesis Staging Sentinel lymph node Prognostic markers New therapeutics and implications for pathologists
2 Differential diagnosis of Merkel cell carcinoma Immunohistochemical studies inform the diagnosis of Merkel cell carcinoma Diagnosis Morphology IHC BCC Peripheral palisading Clefting Melanoma Pigmented Prominent intraepidermal MCPy-T-antigen negative Lacks prominent CK20+ S100+, MART-1+, Sox-10+, HMB-45+ Cytokeratin- Lymphoma/Leukemia Dishesive Positive for lymphoid markers Negative for cytokeratins Sebaceous carcinoma Metastatic neuroendorcine carcinoma Lacks neuroendocrine chromatin CK7+ CK20- and MCPy-T antigen negative Overlapping TTF-1+ CK7+ CDX-2+ MCPy-T-antigen negative CK20 TTF1 CHG SYN Cam5.2 LCA Differential diagnosis of MCC: Basal cell carcinoma Differential diagnosis MCC vs BCC: Cytokeratin 20 Cytokeratin 20 MCC BCC Moll R / Scott /10 0/6 Hanley AJ /21 Yang DT /22 0/19 McNiff JM /10 Poniecka AW /20 Shirren CG /17 Rekhi B / Bobos M / Llombart B / Leech SN / Chan JK / Sidiropoulos M / Sur M / Nicholson SA / TOTALS 212/ % 0/72 0% Also informative: MCPyV T-Ag
3 Differential diagnosis of MCC: Melanoma Differential diagnosis of MCC: Melanoma Mart-1 S100 CK20 Differential diagnosis of MCC: Small Cell Carcinoma Lung Differential diagnosis of MCC: Small Cell Carcinoma Lung Combination of TTF1- and CK20+ Spectrum of lesions with variable positivity for TTF1 and/or CK20. Diagnosis based on clinical history/exam and where the lesion falls on the IHC spectrum. CK20 CK20 TTF1 TTF1
4 Differential diagnosis of MCC: Lymphoma/Leukemia Differential diagnosis of MCC: Lymphoma/Leukemia Differential diagnosis of MCC: Lymphoma/Leukemia Differential diagnosis of MCC: Lymphoma/Leukemia CD3 MCC may (aberrantly) express B-cell markers MCC may stain positively for hematolymphoid markers 70% of MCCs are TdT+ 94% of MCCs are Pax-5+ CD4 CD30 MCC TdT Pax5 Sur M / Sidiropoulos M / Kohle R /27 24/27 Zur Hausen A /21 21/21 Totals 72/103 70% 45/48 94%
5 Demographics of Merkel cell carcinoma MCC is the most aggressive form of skin cancer ~35% of patients with nodal disease at presentation ~10% of patients with systemic metastases at presentation Estimated mortality rate: 33%-46% MCC affects older Caucasian men and is most commonly on the head and neck 70% of patients are >70 years old 62% of patients are male 43% of patients head and neck Risk factors for MCC are age and immunosuppression Elderly Accumulation of mutations from ultraviolet light Organ transplantation, HIV+, CLL Merkel cell polyomavirus (MCPyV) Mutational signature of Merkel cell carcinoma depends on MCPyV In comparison to MCPyV-positive MCCs (n=7): MCPyV-negative MCCs (n=8) A significantly higher mutational burden A UV-type mutational signature Merkel cell carcinoma driven by polyomavirus infection Mutational signature of Merkel cell carcinoma depends on MCPyV In comparison to MCPyV-positive MCCs (n=12): MCPyV-negative MCCs (n=19) Arise on chronic uv-exposed sites Exhibit a much higher mutational burden
6 Mechanisms of Merkel cell carcinomagenesis Common pathways abrogated by distinct mechanisms: mutation or virus Mechanisms of Merkel cell carcinomagenesis Common pathways abrogated by distinct mechanisms: epigenetic or virus MCPyV + MCC Viral inactivation of RB and TP53 related pathways Mutational inactivation of TP53 and RB MCPyV- MCC MCPyV + MCC Viral inactivation of RB and TP53 related pathways Mutational inactivation of TP53 and RB MCPyV- MCC MCPyT MCPyT PRC2 Silences gene regions by methylation (H3K27me) MCPyT MCPyT MCPyVT H3K27me Staging Merkel cell carcinoma Cases with follow-up and complete staging n=9,387 Histopathologic features of Merkel cell carcinoma that correlate with outcome: What do we report and why? Retrospective review of 156 patients with MCC with median follow up 51 months (range: months) Survival directly correlates with overall disease burden Local disease > Nodal metastases > Distant metastases Tumor size (and extent of invasion) define pt-category
7 Histopathologic features of Merkel cell carcinoma that correlate with outcome: What do we report and why? Among patients with lymph node negative early stage MCC (Stage I and II) Pattern of growth (Nodular versus infiltrative) Deepest anatomic compartment of involvement Tumor Lymphovascular invasion Tumor infiltrating lymphocytes (absent vs present) Pathologic staging system for Merkel cell carcinoma Based on pathologic staging of primary and metastatic disease T- pn- pm- Clinical staging system for Merkel cell carcinoma Based on pathologic staging of primary and clinical evidence of metastases T- cn- cm- Metastasis in MCC is relatively common and is an important predictor of survival: The sentinel node Pan-Cytokeratin cocktail Approximately 35% of patients with MCC present with regional nodal metastases
8 Value of immunohistochemical studies in assessing sentinel lymph nodes for MCC 10 patients 23 SLNBs All negative on 1 st H&E IHC for PanCK or CK20 5/23 SLN+ (21.7%) 4/10 patients (40%) Among patients with negative lymph node following examination of initial H&E An additional 40% of patients with lymph node metastases are identified by examining additional tissue levels and immunohistochemical studies with pan-ck or CK20 Pan-Cytokeratin cocktail Value of immunohistochemical studies in assessing sentinel lymph nodes for MCC Pan-Cytokeratin c oc ktail Value of immunohistochemical studies in assessing sentinel lymph nodes for MCC Pan-Cytokeratin cocktail Value of immunohistochemical studies in assessing sentinel lymph nodes for MCC Pan-Cytokeratin cocktail
9 SLN is an important prognostic tool for patients with MCC 59% 76% 42% 26% Lymph node status correlates with outcome Clinically node positive disease fares worst Pathological node negative disease fares best Pattern of sentinel lymph node positivity correlates with survival in Merkel cell carcinoma Pattern 1 Pattern 2 Among patients with lymph node involvement by MCC (H&E or IHC) What are the patterns of involvement? Do these patterns correlate with clinical outcome? What is the significance of metastatic MCC determined only by IHC? Pattern 3 Pattern 4 Pattern 5 Pattern of involvement Metastasis to the SLN in MCC is an important predictor of distant relapse and survival (in most studies) 721 patients 736 SLNBs 218 SLN+ (29.6%) 518 SLN- (70.4%) Regional nodal relapse not significantly different between SLNB+ (11.2%) and SLNB- (8.7%) patients Distant relapse far more frequent among SLNB+ (17.6%) compared to SLNB- (7.3%) patients (p<0.001). Sentinel lymph node status is a robust indicator of distant relapse and overall survival in MCC. Pattern of sentinel lymph node positivity correlates with survival in Merkel cell carcinoma Pattern 1 Pattern 2 Among patients with lymph node involvement by MCC (H&E or IHC) What are the patterns of involvement? Do these patterns correlate with clinical outcome? What is the significance of metastatic MCC determined only by IHC? Pattern 3 Pattern 4 Number of nodes Pattern 5
10 Pattern of sentinel lymph node positivity correlates with survival in Merkel cell carcinoma Pattern 1 Pattern 2 Among patients with lymph node involvement by MCC (H&E or IHC) What are the patterns of involvement? Do these patterns correlate with clinical outcome? What is the significance of metastatic MCC determined only by IHC? Pattern 3 Pattern 4 Age Pattern 5 Prognostic factors in Merkel cell carcinoma: p63 CK20 CHG SYN p63 n= 47 pts with MCC 25 p p63- p63-positive MCCs have worse survival than p63-negative MCCs Pattern of sentinel lymph node positivity correlates with survival in Merkel cell carcinoma Prognostic factors in Merkel cell carcinoma: p63 n= 70 pts with MCC 43 p p63- Assessed for association between survival: Age Gender Anatomic site Tumor size Tumor thickness Cell size LVI Mitotic figures TILS Pattern of growth Stage p63 p53 Ki-67 (MIB1) MCPyVstatus Stage I-II MCC
11 Prognostic factors in Merkel cell carcinoma: p63? Prognostic factors in Merkel cell carcinoma: Not all studies support the prognostic significance of p63 Status of the immune system n= 26 pts with MCC 20 p63+ 6 p63- NO ASSSOCIATION Advanced patient age and male sex associate with worse prognosis(laryngoscope : ) Immunosuppression is a risk factor for developing MCC and correlates with worse outcome independent of stage. n= 128 pts with MCC 42 p p63- All patients Stage I Stage II No significant correlation within a given stage Stage III Stage IV n= 471 pts with MCC n= 430 immunocompetent n= 41 immunosuppressed n=21 CLL/hematologic malignancy n=5 HIV/AIDS n=15 iatrogenic transplant autoimmune Composition and density of the immune system is prognostic Merkel cell carcinoma Composition, density and distribution of the immune infiltrate is prognostic Merkel cell carcinoma n=62 MCCs IHC CD3, CD8, PD-1, and PD-L1 Quantified with Aperio automated image analysis Does the composition, density and/or distribution of the associated immune infiltrate associate with survival in MCC? CD3 IHC CD3 IHC-quantified/mm 2
12 Composition, density and distribution of the immune infiltrate is prognostic Merkel cell carcinoma Leveraging the immune system to treat MCC Immunity and Merkel cell carcinoma Immunosuppression Risk factor for the development of MCC Correlates with worse prognosis independent of stage Immune infiltrates correlate with prognosis Increasing CD8+ T-cells at tumor periphery associates with improved survival Robust frequency of neoantigens in MCC (MCPyV or high mutational burden) Density of the CD8+ T-cell infiltrate at the tumor periphery associates with survival Effect appears to be amplified in MCPyV+ compared to MCPyV- MCCs Leveraging the immune system to treat MCC Response to anti-pd-1 in Merkel cell carcinoma Immunity and Merkel cell carcinoma Immunosuppression Risk factor for the development of MCC Correlates with worse prognosis independent of stage Immune infiltrates correlate with prognosis Increasing CD8+ T-cells at tumor periphery associates with improved survival Robust frequency of neoantigens in MCC (MCPyV or high mutational burden) 56% objective response rate to PD-1 inhibitor among stage IIIb or IV MCC patients who had not received prior systemic therapy independent of MCPyV status or the relative expression of PD-L1.
13 Response to anti-pd-l1 in Merkel cell carcinoma 32% (28/88) patients with stage IV MCC who failed at least one prior systemic therapy achieved rapid and sustained response to PD-L1 inhibitor independent of MCPyV status or the relative expression of PD-L1. FDA approval for MCC Thank you.. Department of Pathology, Section of Dermatopathology, MDACC Victor G. Prieto MD, PhD Carlos A. Torres-Cabala MD Jonathan L Curry MD Priyadharsini Nagarajan MD, PhD Phyu Aung MD, PhD Doina Ivan MD Laurence Feldmeyer, MD, PhD Courtney W. Hudgens, BS Department of Pathology, Cleveland Clinic Steven D Billings MD Jennifer S. Ko MD, PhD Merkel cell carcinoma MCC is the most aggressive form of skin cancer Risk factors are age, exposure and immunosuppression Important parameters of the primary lesion Size, depth, lymphocytic infiltrate, LVI, pattern of growth Staging according to TNM criteria MCC is related to infection by Merkel cell polyoma virus Viral T-antigens impact on Rb and TP53-dependent processes MCPyV-negative MCC enriched for UV-mutations (in particular TP53 and RB) Prognostic biomarkers include: Immune infiltrate p63 expression by tumor cells, but utility is questionable MCC responds to immune checkpoint blockade Thus far, independent of PD-L1 or MCPyV status Complex relationships between MCPyV and TP53 and RB RB expression lost in MCPyV- MCCs but preserved in MCPyV+ MCCs TP53 expression detected (surrogate for TP53 mutation) in MCPyV- MCCs but not in MCPyV+ MCCs. Suggest MCPy machinery interferes with RB and TP53-dependent pathways while MCPyV- MCCs rely on mutational inactivation.
Merkel cell carcinoma: Diagnosis, staging, sentinel lymph node biopsy and prognostic markers
Merkel cell carcinoma: Diagnosis, staging, sentinel lymph node biopsy and prognostic markers Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationMichael T. Tetzlaff MD, PhD
American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary
More informationUpdate on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy
Update on Spitzoid and Blue nevus-like melanocytic lesions Emphasis on molecular studies informing diagnosis, prognosis and therapy Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology,
More informationMichael T. Tetzlaff MD, PhD
Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification
More informationMichael T. Tetzlaff MD, PhD
Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department of Translational and
More informationProtocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin
Protocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin Version: Protocol Posting Date: June 2017 Includes ptnm requirements from the 8 th Edition, AJCC Staging Manual
More informationCytokeratin 20 negative Merkel cell carcinoma consistent with negative Merkel cell polyomavirus
CASE REPORT eissn 2384-0293 Yeungnam Univ J Med 2017;34(2):293-297 https://doi.org/10.12701/yujm.2017.34.2.293 Cytokeratin 20 negative Merkel cell carcinoma consistent with negative Merkel cell polyomavirus
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationMelanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors
Melanoma and the genes: Molecular alterations informing the diagnosis of melanocytic tumors Michael T. Tetzlaff MD, PhD Associate Professor Department of Pathology, Section of Dermatopathology Department
More informationDesmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC
R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o
More informationMelanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018
Melanocytic Lesions: Use of Immunohistochemistry and Special Studies Napa Valley 2018 Victor G. Prieto, MD, PhD Professor Depts. of Pathology and Dermatology University of Texas - MD Anderson Cancer Center
More informationCase 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationCase year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More information46. Merkel Cell Carcinoma
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More informationEpithelial Cancer- NMSC & Melanoma
Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug
More informationPathology of the Thyroid
Pathology of the Thyroid Thyroid Carcinoma Arising from Follicular Cells 2015-01-19 Prof. Dr. med. Katharina Glatz Pathologie Carcinomas Arising from Follicular Cells Differentiated Carcinoma Papillary
More informationProtocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin
Protocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin Protocol applies to Merkel cell carcinoma of cutaneous surfaces only. Based on AJCC/UICC TNM, 7th edition
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More information6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationCutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Skin Malignancies 2/4/2010 NAACCR 2009 2010 Webinar Series Questions Please use the Q&A panel to submit your questions Send questions to All Panelist Collecting Cancer Data: Skin
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationMerkel Cell Carcinoma: Not Just Another Skin Cancer
Merkel Cell Carcinoma: Not Just Another Skin Cancer Merkel cell carcinoma (MCC) is a rare, aggressive, and often fatal neuroendocrine skin cancer. The incidence of MCC has been increasing in recent decades.
More informationClinicopathologic Features of Primary Merkel Cell Carcinoma: A Detailed Descriptive Analysis of a Large Contemporary Cohort
Clinicopathologic Features of Primary Merkel Cell Carcinoma: A Detailed Descriptive Analysis of a Large Contemporary Cohort JENNIFER L. SCHWARTZ, MD,* CHRISTOPHER K. BICHAKJIAN, MD,* LORI LOWE, MD,* KENT
More informationShould we still be performing IHC on all sentinel nodes?
Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami
More information3/27/2017. Pulmonary Pathology Specialty Conference. Disclosure of Relevant Financial Relationships. Clinical History:
Pulmonary Pathology Specialty Conference Saul Suster, M.D. Medical College of Wisconsin Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position
More informationCase Report Clear Cell Basal Cell Carcinoma
SAGE-Hindawi Access to Research Volume 2011, Article ID 386921, 4 pages doi:10.4061/2011/386921 Case Report Clear Cell Basal Cell Carcinoma Deba P. Sarma, 1 Daniel Olson, 1 Jennifer Olivella, 1 Tracey
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationAGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS
AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS PAPILLARY THYROID CARCINOMA Clinical Any age Microscopic to large Female: Male= 2-4:1 Radiation history Lymph nodes Prognosis
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationGastric and Oesophageal Neuroendocrine tumours. Dr Tim Bracey, Consultant Pathologist MBChB PhD MRCS FRCPath
Gastric and Oesophageal Neuroendocrine tumours Dr Tim Bracey, Consultant Pathologist MBChB PhD MRCS FRCPath Intestinal (and BO) endocrine cells in crypt bases NE cell (granules towards vessels) Paneth
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More information64 y.o. F with CLL and leg tumour
64 y.o. F with CLL and leg tumour Case History Excision with split-skin grafting Histology moderately differentiated squamous cell carcinoma with large areas of necrosis and brisk mitotic activity.
More informationWhat are the new AJCC Staging System changes, and how will they affect my patients?
What are the new AJCC Staging System changes, and how will they affect my patients? Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine University of Pennsylvania
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationCollaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]
CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's
More informationUpdate on SLN and Melanoma: DECOG and MSLT-II. Gordon H. Hafner, MD, FACS
Update on SLN and Melanoma: DECOG and MSLT-II Gordon H. Hafner, MD, FACS No disclosures The surgery of malignant disease is not the surgery of organs, it is of the lymphatic system. Lord Moynihan Lymph
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationFinancial disclosures
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchc Geisel School of
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationNo Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma
No Benefit to Routine Completion Lymphadenectomy for Sentinel Lymph Node Positive Melanoma Michael Lowe, MD Assistant Professor of Surgery Winship Cancer Institute Emory University School of Medicine July
More informationMalignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha
Malignant tumors of melanocytes : Part 3 Deba P Sarma, MD., Omaha Let s go over one case of melanoma using the following worksheet. Of the various essential information that needs to be included in the
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationHematolymphoid lesions of the skin Part II Myeloid neoplastic proliferations Houston Society of Clinical Pathologists Symposium April 14, 2018
Hematolymphoid lesions of the skin Part II Myeloid neoplastic proliferations Houston Society of Clinical Pathologists Symposium April 14, 2018 Carlos A. Torres-Cabala, MD Associate Professor Chief, Dermatopathology
More information- Selected Tumors of the Skin Appendages - Primary vs. Metastasis
- Selected Tumors of the Skin Appendages - Primary vs. Metastasis Napa Valley 2018 Victor G. Prieto, MD, PhD Chair of Pathology UT MD Anderson Cancer Center vprieto@mdanderson.org Napa Valley in May Introduction
More informationHead & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda
Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University
More information6/22/2015. Original Paradigm. Correlating Histology and Molecular Findings in Melanocytic Neoplasms
6 Correlating Histology and Molecular Findings in Melanocytic Neoplasms Pedram Gerami MD, Associate Professor of Dermatology and Pediatrics at Northwestern University Disclosures: I have been a consultant
More informationAtypical Palisaded Myofibroblastoma of Lymph Node: Report of a rare case.
ISPUB.COM The Internet Journal of Pathology Volume 10 Number 1 Atypical Palisaded Myofibroblastoma of Lymph Node: Report of a rare case. V Kinnera, R Nandyala, M Yootla, K Mandyam Citation V Kinnera, R
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationThis form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationWhitney A. High, MD, JD, MEng
ADS Dermatopathology Meeting 2014 Selected Adnexal Tumors Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado School
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationCutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationLUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
More informationUnknown Slides Conference
Unknown Slides Conference Jae Y. Ro, MD, PhD Weill Medical College of Cornell Univ. The Methodist Hospital, and UT MD Anderson Cancer Center Houston, TX November 9, 2013 Amman, Jordan 25 th Congress of
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationSurgery for Melanoma and What s on the Horizon
and What s on the Horizon Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background/Overview 76,870 cases of melanoma estimated
More informationThe clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationAn Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center
An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationUpdate on Lymph Node Management in Melanoma
Update on Lymph Node Management in Melanoma John T. Vetto MD, FACS Professor of Surgery Division of Surgical Oncology Oregon Health & Science University Portland, Oregon Lymph Nodes in Melanoma Outline
More informationDisclosure of Relevant Financial Relationships
Squamous entities of the thyroid: Reactive to Neoplastic Michelle D. Williams Associate Professor Dept of Pathology, Head & Neck Section University of Texas MD Anderson Cancer Center Disclosure of Relevant
More informationModalities of Radiation
Modalities of Radiation Superficial radiotherapy Orthovoltage Megavoltage Photons Electrons Brachytherapy Interstitial Moulds When to refer? The vast majority of skin cancers will be managed without any
More informationProblems in staging breast carcinoma
Problems in staging breast carcinoma Primary systemic therapy (PST) of breast carcinoma pathologists tasks Dr. Janina Kulka, 2nd Department of Pathology, Semmelweis University Budapest Austro-Hungarian
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationGreater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14
Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14 Contents 14. Neuroendocrine Tumours 161 14.1. Diagnostic algorithm
More informationCase 2. Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset
Case 2 Dr. Sathima Natarajan M.D. Kaiser Permanente Medical Center Sunset History 24 year old male presented with a 3 day history of right flank pain, sharp in nature Denies fever, chills, hematuria or
More informationPaul Nghiem, MD, PhD, University of Washington, Seattle, WA
Merkel Cell Carcinoma: Diagnosis, Management and Controversies Forum F011; Room: D237 Friday, March 01, 2013, 10:00 12:00 pm American Academy of Dermatology Annual Meeting Miami, FL Version 2/25/13 Director:
More informationPatricia Chevez-Barrrios AAOOP-USCAP /12/2016
Biomarkers in Ocular Melanoma Patricia Chévez-Barrios, MD Pathology and Genomic Medicine, Houston Methodist Hospital Professor of Pathology and Laboratory Medicine and Ophthalmology, Weill Cornell Medical
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationWhat I Learned from 3 Cases and 3 Antibodies
What I Learned from 3 Cases and 3 Antibodies Melinda Sanders, M.D Vanderbilt University Medical Center Professor of Pathology Consultant in Breast Pathology Disclosure of Relevant Financial Relationships
More informationNasreen A. Syed, MD F.C. Blodi Eye Pathology Laboratory University of Iowa
Nasreen A. Syed, MD F.C. Blodi Eye Pathology Laboratory University of Iowa No financial disclosures No discussion of off-label use of medications or unapproved devices 67 year old male referred to Oculoplastics
More informationMody. AIS vs. Invasive Adenocarcinoma of the Cervix
Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive
More informationNeuroendocrine Lung Tumors Myers
Diagnosis and Classification of Neuroendocrine Lung Tumors Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of Michigan, Ann Arbor, MI myerjeff@umich.edu
More informationCutaneous Adnexal Tumors
Cutaneous Adnexal Tumors Lesions with Predominant Follicular Differentiation Special Emphasis on Basal Cell Carcinoma 2014-04-01 Prof. Dr. med. Katharina Glatz Pathologie Cutaneous Adnexal Tumors Hair
More information